Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors
Article content
Two-Part Dose Escalation and Expansion Trial Will Evaluate Efficacy and Safety of BYON4228 Alone and in Combination with Pembrolizumab
Article content
Article content
NIJMEGEN, The Netherlands — Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose escalation and expansion BYON4228.002 clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of novel SIRPα-directed monoclonal antibody (mAb) BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
Article content
BYON4228 is a potential best-in-class novel mAb that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. By targeting SIRPα and not CD47, BYON4228 offers selective targeting of myeloid cells and avoids disruption of other biologically meaningful CD47-dependent interactions. In preclinical studies, BYON4228 was found to potentiate the tumor killing capacity of tumor-targeting mAbs tested without the toxicity associated with CD47 agents.
Article content
'Building on strong preclinical data, we believe that there is broad potential for BYON4228 alone and in combination with tumor-targeting mAbs, checkpoint inhibitors and antibody drug conjugates and other modalities across hematological and solid tumors,' said Louis Denis, MD, Chief Medical Officer, Byondis. 'We look forward to evaluating the results of this trial to support the clinical development of BYON4228 alone and in combination with other agents and to bring a new therapeutic option to patients with high unmet medical need.'
Article content
Part 1 of the BYON4228.002 trial will evaluate the safety of BYON4228 alone and in combination to determine the maximum tolerated dose (MTD), or optimal biological dose (OBD) if the MTD is not reached, and recommended combination dose regimen(s) for expansion (RDE(s)). The second part of the trial will evaluate the objective tumor response rate (ORR). The secondary objectives of this trial are safety, pharmacokinetics, immunogenicity and preliminary efficacy. The trial will be conducted at multiple sites across Europe, including the United Kingdom, Belgium and Spain.
Article content
BYON4228 is a novel monoclonal antibody (mAb) from Byondis' next generation immuno-oncology (IO) program that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. BYON4228 is currently being studied in two Phase 1 Clinical Trials evaluating BYON4228 alone and in combination with Rituximab in patients with Relapsed/Refractory CD20 positive B-cell Non-Hodgkin's Lymphoma (NHL) (NCT05737628) and BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors (NCT06932952).
Article content
Driven to improve patients' lives, Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.
Article content
Byondis' broad development portfolio comprises preclinical and early-stage clinical programs. The product candidates combine Byondis' expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis' expertise covers all preclinical R&D from early lead finding to production of clinical batches of the selected product candidates, which are all done in-house.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
19 minutes ago
- CTV News
Ticats GM says he has been diagnosed with ‘a serious form of cancer'
Hamilton Tiger-Cats general manager Ted Goveia says he has been diagnosed with "a serious form of cancer that's spread." In a story posted on the club's website Friday, Goveia, 55, said the diagnosis was made in April. Although there was no specific mention as to the form of the disease, two league sources said Goveia is battling esophageal cancer. "I wanted to keep my health condition in house until we had a chance to build our team and pick our final roster," he said. "I am grateful that we were able to focus on fielding the best team possible for 2025 and not have my health become a distraction. "I let the players know that I'm not going to be here (at team facilities) every minute of the day, and I'm going to be in treatment and need to focus on my health. I'm still the general manager, but I'll not always be in the building. But in today's day and age, everything's downloaded to my laptop and there's always the phone." Goveia, of Burlington, Ont., was named Hamilton's GM on Dec. 5, 2024, following 11 years with the Winnipeg Blue Bombers. The appointment was a homecoming for Goveia, who played high school football at Assumption Secondary School and later coached there as well as other local organizations. Goveia's early days as Ticats' GM were long and busy as he put together a staff while looking to improve a roster that last year missed the CFL playoffs. All the while getting to know the people in his new workplace. But in March, Goveia told The Canadian Press he never had to look far to gain a sense of perspective or appreciation that he'd landed his dream job. 'The other morning I went into the office at 6:30 a.m.,' Goveia said. 'Got up, grabbed my coffee and drove over the (Burlington Skyway) bridge and I'm looking out and the sun was coming up. 'I just sat there smiling as I drove thinking, 'Man, I'm 17 minutes from home.' I do love southern Ontario and appreciate the opportunity to work back at home, for sure.' Hamilton (7-11) missed the 2024 CFL playoffs and last won the Grey Cup in 1999. "Our CFL family and the entire CFL community sends its best wishes to Ted Goveia after learning of his cancer diagnosis," CFL commissioner Stewart Johnston said in a statement. "Fans from coast to coast to coast send their strength to you and your family. "Your journey through the game has been an incredible inspiration to us all, and we're here now to support you every step of the way throughout this courageous fight." Goveia began his tenure in Winnipeg as the club's assistant GM/player-personnel director before being promoted to senior assistant GM in 2019 following the franchise's 33-12 Grey Cup win over Hamilton. Goveia said being away from the team while undergoing treatment will only serve to motivate him in his fight. "I enjoy being around our players and I will miss the daily interaction — it motivates me to kick this and get back with the team," he said. "I feel like we're in good shape, but I did have to meet with everybody in the building because I thought they had the right to know. "As difficult a conversation as it is to have, I owe that to the players and to the people who are working here.' And Goveia said the Ticats are in very good hands at this time. "I'm not at all concerned that we're going to be able to function well throughout this,' he said. "I don't have one worry about that. "I feel like we're in good shape, and I think we've got a bunch of rising stars (in football operations)." Goveia began his CFL career with the Toronto Argonauts in 2010, serving as running backs coach and director of Canadian scouting before being promoted to player-personnel director. Over his four seasons with the club (2010-13), it reached the playoffs three times and captured the 100th Grey Cup in 2012 under then-head coach Scott Milanovich, who's entering his second season as Hamilton's head coach/offensive co-ordinator. Goveia would later be on two Grey Cup-winning squads in Winnipeg (2019, 2021). Before making the move to the CFL, Goveia spent 15 years coaching Canadian university football, including stops at his alma mater, Mount Allison, McMaster, and the University of British Columbia. This report by The Canadian Press was first published June 6, 2025. Dan Ralph, The Canadian Press
National Post
3 hours ago
- National Post
What eating foods like dark chocolate and berries did to a study group of more than 120,000 people
A new study reveals what drinking tea and eating dark chocolate and berries did for a group of more than 120,000 people. Article content Those foods, as well as fruits like grapes, apples, oranges, and beverages like red wine, all contain flavonoids, which are compounds found in many plant products. Flavonoids can 'help your body function more efficiently while protecting it against everyday toxins and stressors,' per Healthline. The study's authors said those who consumed a diverse range of foods containing flavonoids (such as berries, grapes and dark chocolate) 'could lower their risk of developing serious health conditions and have the potential to live longer,' in a news release. The study has been peer-reviewed. Article content Article content Article content In the study, which was recently published in the journal Nature Food, researchers observed 124,805 participants between the ages of 40 and 70 from the UK Biobank, a large-scale database with biomedical information. The participants were tracked for roughly 10 years and their dietary information was collected using a questionnaire asking them about the frequency in which they ate approximately 200 types of food and 30 beverages. Article content Article content Dr. Benjamin Parmenter, a research fellow at Edith Cowan University in Australia, was the study's first author and co-lead. He said consuming roughly 500 mg of flavonoids a day or more was linked to a 16 per cent lower risk of 'all-cause mortality' (meaning death from any cause). Article content It was also linked to a roughly 10 per cent lower risk of cardiovascular disease, type 2 diabetes, and respiratory disease. Article content A study published in 2025 in peer-reviewed food science journal Foods said, as it pertains to human health, 'flavonoids are recognized for their ability to combat aging, mitigate inflammation, safeguard the nervous system, and promote overall well-being.' However, in another study published in 2022 in the Nutrition Journal, researchers 'observed an increased risk of prostate cancer by higher intake of total flavonoids.' In a study published in 2016 in the Journal of Nutritional Science, researchers called for further studies on flavonoids so their usefulness 'in the diet could be improved for better human health.' Article content Article content 'Over 30 different types of flavonoids are regularly consumed in the human diet. These are found in different types of everyday foods,' Parmenter told National Post over email. Article content Article content A few squares of dark chocolate could be roughly 25 mg of flavonoids. One apple is equal to roughly 100 mg of flavonoids, while one orange is roughly 60 mg. For tea drinkers, one cup of black tea is roughly 300 mg of flavonoids, while the same amount of green tea is roughly 150 mg. Article content 'We observed that consuming a higher quantity and wider diversity of dietary flavonoids, when consumed together, may represent the optimal approach for improving long-term health, compared with increasing either flavonoid quantity or diversity alone,' Parmenter said. Article content Those with the highest flavonoid diversity were more likely to be female, older, have a lower body mass index (BMI), be more physically active and have a higher education and were less likely to be current smokers, according to the study.
Globe and Mail
3 hours ago
- Globe and Mail
Industrial Control & Factory Automation Market worth $399.12 Billion by 2029, at a CAGR of 9.3%
"Industrial Control & Factory Automation Market" The global Industrial Control & Factory Automation Market in terms of revenue is estimated to be worth $255.88 billion in 2024 and is poised to reach $399.12 billion by 2029, growing at a CAGR of 9.3% during the forecast period. The report " Industrial Control & Factory Automation Market by Technology (SCADA, DCS, HMI, MES, PAM, WMS, Industrial Robotics, 3D Printing, CNC Controller, Process Analyzer, Flow meter, Communication, Predictive Maintenance, Machine Safety) - Global Forecast to 2029" The global industrial control & factory automation market is anticipated to grow from USD 255.88 billion in 2024 to USD 399.12 billion by 2029, at a CAGR of 9.3% during the forecast period. Download PDF Brochure @ Browse 160 market data Tables and 60 Figures spread through 336 Pages and in-depth TOC on "Industrial Control & Factory Automation Market" View detailed Table of Content here - Several key factors are driving the Industrial Control and Factory Automation Industry, including increased IoT and Al integration in industrial environments, a growing emphasis on operational efficiency and productivity, and significant and ongoing government investments in 3D printing technologies, all of which are contributing to market growth. With the emergence of new technologies in firms, regulatory compliance regarding industrial solutions of immense significance is also involved. There is a growing need for innovative techniques to reduce production downtime and waste. For instance, the use of real-time data analytics in factories help companies optimize operations hence efficiency while reducing production waste. Distributed control system (DCS) segment is expected to account for the largest share of the Industrial control & factory automation market during the forecast period. The industrial control system further segmented into Supervisory Control and Data Acquisition (SCADA), Distributed Control System (DCS), Programmable Logic Controller (PLC), Industrial PC, Human Machine Interface. A distributed control system (DCS) is expected to account for the largest share, which is an industrial automation solution primarily deployed in process industries to facilitate plant control through a distributed network of supervisory and control elements. DCS systems are vital for optimizing operational processes by distributing control across various plant sections. The market for DCS is driven by the need for operational efficiency, integration of advanced technologies, regulatory compliance, and the expansion of industrial infrastructure. Aerospace industry segment to exhibit highest CAGR in the forecast year. As the need for both commercial and defense aircraft grows, manufacturers are turning to enhanced automation to reach production targets more effectively. Automated systems enhance safety and precision in vital activities such as navigation and propulsion, greatly decreasing human error. Furthermore, automation is critical for cost management, speeding production processes like as assembly and testing, and maximizing the usage of innovative materials such as composites. The use of Al-driven digital twins improves real-time monitoring by increasing reliability and minimizing downtime. Asia Pacific is expected to hold the largest market share of the industrial control & factory automation market during the forecast period. The growth of industrial control & factory automation market in Asia Pacific can be attributed to rapid industrialization, commercialization of IIoT applications and increasing adoption of industrial robot. Asia Pacific is a manufacturing hub; hence, motor vehicle suppliers, such as Toyota (Japan), Renault-Nissan (Netherlands), and Daimler (Germany), Volkswagen (Germany), and local manufacturers, such as Tata Motors (India) and Hyundai Motors (South Korea), invest heavily in the smart factory market in Asia Pacific. The majority of prominent manufacturers from various industries have relocated their manufacturing operations to Asia Pacific due to the region's low labor costs and availability of trained workers. Furthermore, governments across the area are encouraging Industry 4.0 and Industrial control & factory automation efforts through laws, incentives, and subsidies. Programs such as Made in China 2025 and make in India are encouraging industries to adopt advanced automation technologies like robotics, AI, and IoT to enhance competitiveness and productivity. The key players in the Industrial Control & Factory Automation Companies include ABB (Switzerland), Emerson Electric Co. (US), General Electric (US), Honeywell International Inc. (US), and Siemens (Germany). About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook.
